Newron Pharmaceuticals S.p.A.
SIX: NWRN.SW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Swiss Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stefan Weber
- Employees
- 22
- Headquarters
- Bresso, Italy
- IPO year
- 2006
- Market cap
- CHF 283.0M
- Website
- https://www.newron.com
Loading NWRN…
Loading profile data…Frequently asked questions about NWRN
What does Newron Pharmaceuticals S.p.A. (NWRN.SW) do?
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the tr...
Where does NWRN.SW trade?
Newron Pharmaceuticals S.p.A. (NWRN.SW) trades on the Swiss Exchange.
What sector is NWRN.SW in?
Newron Pharmaceuticals S.p.A. (NWRN.SW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Newron Pharmaceuticals S.p.A.?
Stefan Weber is the chief executive officer of Newron Pharmaceuticals S.p.A. (NWRN.SW).
Where is Newron Pharmaceuticals S.p.A. headquartered?
Newron Pharmaceuticals S.p.A. is headquartered in Italy.
Does NWRN.SW pay a dividend?
Newron Pharmaceuticals S.p.A. (NWRN.SW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NWRN.SW go public?
Newron Pharmaceuticals S.p.A. (NWRN.SW) completed its initial public offering in 2006.